ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02280408
Recruitment Status : Completed
First Posted : October 31, 2014
Last Update Posted : January 18, 2017
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
BioProtection Systems Corporation
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola vaccine VSV ZEBOV (BPSC-1001) to see if it is safe and to see how it affects people's immune system.

Condition or disease Intervention/treatment Phase
Ebola Viruses Other: Placebo Biological: BPSC-1001 Vaccine Phase 1

Detailed Description:

Between 1994 and the present, there have been many Ebola virus (EBOV) outbreaks affecting mostly central Africa. However, the 2014 West African outbreak significantly exceeds all previous outbreaks in geographic range, number of individuals affected and in disruption of typical activities of civil society.

This is a Phase 1 safety and tolerability study to evaluate a novel vaccine to Ebola using a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola (VSVΔG-ZEBOV also known as BPSC-1001).


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults
Study Start Date : October 2014
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ebola

Arm Intervention/treatment
Experimental: 3x10^6 pfu Vaccine Cohort
Participants will receive a 1-mL intramuscular injection of BPSC-1001 3x10^6 pfu in the deltoid on Day 0 and Day 28.
Biological: BPSC-1001 Vaccine
Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.

Experimental: 2x10^7 pfu Vaccine Cohort
Participants will receive a 1-mL intramuscular injection of BPSC-1001 2x10^7 pfu in the deltoid on Day 0 and Day 28.
Biological: BPSC-1001 Vaccine
Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.

Experimental: 1x10^8 pfu Vaccine Cohort
Participants will receive a 1-mL intramuscular injection of BPSC-1001 1x10^8 pfu in the deltoid on Day 0 and Day 28.
Biological: BPSC-1001 Vaccine
Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.

Placebo Comparator: Placebo Cohort
Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
Other: Placebo
Normal saline placebo.




Primary Outcome Measures :
  1. Percentage of Participants with One or More Adverse Event by Severity [ Time Frame: Up to Day 56 ]
  2. Percentage of Participants with One or More Serious Adverse Event [ Time Frame: Up to Day 56 ]
  3. Percentage of Participants with One or More Local Injection-site Adverse Event by Severity [ Time Frame: Up to 14 days after each vaccination ]
  4. Percentage of Participants with One or More Systemic Adverse Event by Severity [ Time Frame: Up to 14 days after each vaccination ]
  5. Percentage of Participants with Early Discontinuation of Vaccination [ Time Frame: Up to Day 28 ]

Secondary Outcome Measures :
  1. Geometric Mean Titers of ZEBOV-specific Neutralizing Antibodies [ Time Frame: Day 28 and Day 56 ]
  2. Geometric Mean Titers of ZEBOV-specific Antibodies [ Time Frame: Day 28 and Day 56 ]
  3. Mean Copy Number of Vector RNA (Vector Viremia) [ Time Frame: Up to Day 35 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:
  • Healthy male or females, ages 18 to 65 (inclusive) at the time of screening
  • Females of childbearing potential and all males, must be willing to use effective methods of contraception, from at least 14 days prior to vaccination through Day 56 which would include:

    • Oral contraceptives, either combined or progestogen alone
    • injectable progestogen
    • implants of etonogestrel or levonorgestrel
    • oestrogenic vaginal ring
    • percutaneous contraceptive patches
    • intrauterine device or intrauterine system
    • male partner sterilization
    • male condom combined with a spermicide
  • Must be willing to minimize blood and body fluid exposure of others for at least 7 days after vaccination, which includes:

    • Use of effective barrier prophylaxis, such as latex condoms, during any sexual interaction (regardless of childbearing status or sexual orientation)
    • Avoiding the sharing of needles, razors, eating utensils, drinking from the same cup, or toothbrushes
    • Avoiding open-mouth kissing
  • Must be willing to forgo blood donation for one year
  • Must agree not to enroll in another study of an investigational agent prior to completion of Day 56 and not participate in an investigational vaccine study until the last required protocol visit on Day 365
  • Ability to provide informed consent

EXCLUSION CRITERIA:

FACTORS THAT INCREASE RISK TO THE SUBJECT:

  • Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:

    • A process that would affect the immune response
    • A process that would require medication that affects the immune response
    • Any contraindication to repeated injections or blood draws
    • A condition that requires active medical intervention or monitoring to avert grave danger to the participant s health or well-being during the study period
    • A condition or process for which signs or symptoms could be confused with reactions to vaccine
    • Any condition specifically listed among the exclusion criteria below
    • Active malignancy
    • Asplenia
    • History of Guillain-Barré Syndrome
    • History of neurological or neuropsychiatric disorder that may either increase risk (history of encephalitis, narcolepsy, stroke, depression, bipolar disorder, seizure, etc.) or could interfere with the assessment of safety (e.g., frequent headaches)
    • History of autoimmune disease
    • History of hemoglobinopathy or a coagulopathy
  • Women who are breast-feeding
  • Positive urine or serum pregnancy test
  • Abnormal chemistry panel; defined as:

    • Defined as any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table
    • Evaluating only creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, and estimated glomerular filtration rate
  • Abnormal complete blood count (CBC) defined as:

    • Defined as any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table
    • Evaluating only the white blood cell (WBC), hemoglobin, hematocrit, and platelets
  • Abnormal urinalysis defined as:

    • Defined as any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table
    • Evaluating red blood cells (RBC), protein, and glucose only
  • Positive serology for hepatitis B surface antigen
  • Positive serology for hepatitis C
  • Positive serology for human immunodeficiency virus (HIV)
  • Known allergy to the components of the VSVΔG-ZEBOV vaccine (BPSC1001) vaccine product (VSV, albumin, tris)
  • History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions

FACTORS THAT MAY LIMIT VSB REPLICATION OR MAKE INTERPRETATION OF IMMUNOGENICITY DIFFICULT:

  • History of prior infection with a filovirus or prior participation in a filovirus vaccine trial
  • Veterinarian or ranchers exposed to livestock known to be infected with VSV
  • History of prior infection with VSV or receipt of a VSV vectored vaccine

FACTOR THAT WOULD INCREASE RISK TO OTHERS DUE TO VSB VIRAL SHEDDING:

  • Is a healthcare worker who will have direct contact with patients within 14 days of each vaccination
  • Is an animal care worker, who will have direct contact with animals (livestock or domestic, besides subjects family pet) within 14 days of each vaccination
  • Has a house-hold contact (HHC) who is immunodeficient (in the opinion of the investigator), pregnant, has an unstable medical condition, or is under the age of 5 years
  • Is a childcare worker who has direct contact with children 5 years of age or younger

FACTORS THAT COULD IMPAIR INTERPRETATION OR EXECUTION OF THE STUDY:

  • Receipt of any investigational drug within 5 half lives or 30 days, whichever is longer, prior to study drug administration (i.e., Day 0)
  • Receipt of licensed vaccines 14 days before the planned study immunization
  • Receipt of immunoglobulins and/or any blood products within the 120 days preceding study entry or that are planned during the study period
  • Immunosuppressive medications received within 168 days before first vaccination. (Not including: [1] corticosteroid nasal spray for allergic rhinitis; [2] topical corticosteroids for mild, uncomplicated dermatitis; or [3] oral/parenteral corticosteroids given for non-chronic conditions not expected to recur [length of therapy 10 days or less with completion at least 30 days prior to vaccination(s)].)
  • Allergy treatment with antigen injections within 30 days before first vaccination or that are scheduled through Day 56
  • Participants who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02280408


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
National Institute of Allergy and Infectious Diseases (NIAID)
BioProtection Systems Corporation
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT02280408     History of Changes
Other Study ID Numbers: V920-002
NLG0207 (Study 15-1-0001) ( Other Identifier: NewLink Genetics Corp. )
First Posted: October 31, 2014    Key Record Dates
Last Update Posted: January 18, 2017
Last Verified: January 2017

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs